Avalyn Pharma Inc. opened the market with a 44% surge as investors rushed to the newly listed shares, reflecting strong demand for the biopharmaceutical firm’s debut in the U.S. market.

The company raised $300 million through an upsized initial public offering, a move that places it among the higher‑valued biotech listings of the year. The spike underscores investors’ appetite for promising science companies.

This jump provides Avalyn with fresh capital to accelerate research and development, potentially speeding up the launch of its pipeline candidates. The influx of funds also signals confidence in the company’s long‑term prospects.

Overall, the IPO not only delivers a hefty return for early backers but also strengthens Avalyn’s balance sheet, positioning it to compete more aggressively in the crowded therapeutics arena.